Ocular Therapeutix (OCUL) Q2 2024 Earnings
OCUL·Reported August 7, 2024·Before market open
Ocular Therapeutix reported Q2 2024 revenue of $16.4M, beat analyst consensus of $15.8M by $621.0K. Diluted EPS came in at $-0.24, missed the $-0.22 consensus by $0.02.
Revenue
$16.4Mbeat by $621.0K
Consensus: $15.8MDiluted EPS
$-0.24missed by $0.02
Consensus: $-0.22
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Ocular Therapeutix's Q2 2024 earnings report.
Ocular Therapeutix (OCUL) reported Q2 2024 earnings on August 7, 2024 before market open.
Ocular Therapeutix reported revenue of $16.4M and diluted EPS of $-0.24 for Q2 2024.
Revenue beat the consensus estimate of $15.8M by $621.0K. EPS missed the consensus estimate of $-0.22 by $0.02.
You can read the 10-Q periodic report (0001558370-24-011202) directly on SEC EDGAR. The filing index links above go to sec.gov.